Study identifier:D2600C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of oral AZD2423 after Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers
Healthy Volunteer
Phase 1
Yes
AZD2423, Placebo
All
32
Interventional
20 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1. AZD2423 | Drug: AZD2423 oral solution, single dose |
Placebo Comparator: 2. Placebo | Drug: Placebo oral solution,single dose |